New Systemic Therapies in Salivary Gland Cancer

Abstract

AbstractSalivary gland cancer (SGC) encompasses a group of rare malignancies with distinct molecular, histologic, and clinical characteristics. Rarity as well as evolving disease heterogeneity have made treatments particularly challenging, with classic chemotherapy agents showing at best moderate antitumor efficacy in patients with recurrent or metastatic SGC. Recent advances in genomic profiling have provided relevant targets for different subtypes of SGC, enabling tailoring of therapeutic approaches. Despite the lack of predictive biomarkers, treatment with immune checkpoint inhibitors also appears to benefit a subgroup of patients. This chapter aims to give a comprehensive overview of novel approaches to systemic therapy for patients with recurrent or metastatic SGC.